Report Description of the Global Defibrillator Market

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Research Objective:

• To analyze and forecast the market size of Global Defibrillator market


• To classify and forecast Global Defibrillator market based on application, drugs, project type, and application.


• To identify drivers and challenges for Global Defibrillator market


• To examine competitive developments such as mergers and acquisitions, agreements, collaborations and partnerships, etc., in Global Defibrillator market


• To conduct pricing analysis for Global Defibrillator market


• To identify and analyze the profile of leading players operating in Global Defibrillator market

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for oncology drug market


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the oncology drug market


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy-based consulting analysis

Global Defibrillator Market Executive Summary

According to data published by the National Institutes of Health in 2016, an estimated 450,000 people suffer due to sudden cardiac death. Since the prevalence and incidence of out-of-hospital cardiac arrest are increasing, developed as well as emerging nations are strictly focusing on installations of external defibrillators in public places such as schools, hotels, shopping malls, streets, and others. Combined with this, education is being offered in schools to spread awareness about them amongst children with the aim to deal with cardiac arrests, which is expected to offer a significant amount of opportunity for the growth of the defibrillator market by 2026

Market Size and Key Findings

The Global Defibrillator market size is at around USD 11.4 billion in 2021 and is projected to reach USD 18.2 billion in 2026, exhibiting a CAGR of 9.7% during the forecast period.

The rising prevalence of target diseases, growing focus on providing public-access defibrillators, and training and awareness programs on defibrillators. In addition, emerging markets and the development of S-ICDs and MRI-compatible ICDs & CRT-Ds are expected to offer growth opportunities for players in the defibrillators market.



Market Dynamics

Market Growth Drivers Analysis

Growing focus towards public access defibrillator (PAD) by the public and private organizations has fueled the market growth. Moreover, increase in number of key players to develop advanced defibrillator devices, rapidly growing geriatric population with elevated risk of cardiac arrest and increase in incidence of cardiac diseases further drive the market growth. Defibrillators are capable of performing cardioversion, defibrillation, and pacing of the heart. External defibrillators are of three major types, namely manual external defibrillator, automated external defibrillator (AEDs), and wearable cardioverter defibrillator (WCDs). AEDs are used for the treatment of sudden cardiac arrest (SCA) due to its high efficiency and ease in use, thereby bagging a large market share in the global defibrillator market.

Market Restraints

Issues related to the use of implantable and automated external defibrillators like AEDs installed in public places are sometimes prone to failure due to problems pertaining to the battery, software, and hardware and cybersecurity concerns are major concern in the defibrillators market. Furthermore, increase in pricing pressure on players is restraining the growth of the defibrillators market. anticipated to obstruct growth.

COVID-19 impact on "Global Defibrillator Market

The COVID-19 outbreak is anticipated to have a negative impact on growth of the global defibrillators market. The outbreak of COVID-19 has disrupted workflows in the healthcare sector globally. The pandemic affected the buying capacities of hospitals, particularly in small-scale hospitals, resulting in canceled or postponed supply deals and procedure, which has impacted the overall revenue of all the major players in the defibrillators market.

Competitive Landscape

Key Players

Prominent players in the defibrillators market include Medtronic (Ireland), Stryker Corporation (US), Koninklijke Philips N.V. (Netherlands), Asahi Kasei Corporation (Japan), Boston Scientific Corporation (US), Abbott (US), Nihon Kohden (Japan), MicroPort (China), BIOTRONIK (Germany), CU Medical Systems (South Korea), METsis Medikal (Turkey), Mediana Co. Ltd. (Korea), Mindray Medical International Ltd. (China), Progetti SRL Medical Equipment Solutions (Italy), and Schiller AG (Switzerland).

Products in Pipeline

REFINE-ICD: GE Healthcare

The product is in pipeline to evaluate whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack in the prior 5 years, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function. The REFINE ICD trial will assess whether prophylactic ICD therapy, guided by non-invasive risk assessment tools, reduces mortality in MI survivors with better-preserved LV function. The study is estimated to be complete by December 2021.

MADIT S-ICD: Boston Scientific Corporation

The MADIT S-ICD trial is designed to evaluate if subjects with a prior myocardial infarction, diabetes mellitus and a relatively preserved ejection fraction of 36-50% will have a survival benefit from receiving a subcutaneous implantable cardioverter defibrillator (S-ICD) when compared to those receiving conventional medical therapy. The study is estimated to be completed by December 2023.

Notable Recent Deals

July 2021-ZOLL Medical Corporation, announced that the company has received clearance from FDA 510(k) to release the TBI (traumatic brain injury) Dashboard feature on its Propaq M monitor and Propaq MD defibrillator. This feature provides clinical decision support for managing patients with TBI and was available in international markets but with the FDA clearance it is now available in U.S. market.

March 2021- The Rankin government made an announcement that all public schools in Nova Scotia a will be provided automated external defibrillators. The government made an investment of USD 700,000. The purpose of this investment is the availability of these devices at the time of cardiac emergency.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario of Global Defibrillator Services

Centers for Medicare and Medicaid Services(CMS), which is a part of the US department of health and human services, provides reimbursement for the wearable defibrillator across a number of high-risk patient groups.

The U.S. Food and Drug Administration issued several regulations on AEDs, including required premarket approval for new and existing AEDs (2015) and necessary accessories (2020) after reports of failing or malfunctioning devices. Some issues were due to manufacturing problems, while others were due to improper maintenance such as battery failure.